First human test of NRS 033 begins: safety first in healthy volunteers
NCT ID NCT05724797
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This early-phase study tested a single dose of the experimental drug NRS 033 in 24 healthy adults aged 18 to 55. The main goal was to check for side effects and measure how the drug moves through the body. No treatment was given for any disease, so this study helps lay the groundwork for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Frontage Clinical Research Center
Secaucus, New Jersey, 07094, United States
Conditions
Explore the condition pages connected to this study.